SG153848A1 - Aequorin-containing compositions and methods of using same - Google Patents
Aequorin-containing compositions and methods of using sameInfo
- Publication number
- SG153848A1 SG153848A1 SG200904273-0A SG2009042730A SG153848A1 SG 153848 A1 SG153848 A1 SG 153848A1 SG 2009042730 A SG2009042730 A SG 2009042730A SG 153848 A1 SG153848 A1 SG 153848A1
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- aequorin
- same
- containing compositions
- preventing
- Prior art date
Links
- 108010000239 Aequorin Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/872,795 US20060229243A1 (en) | 2004-06-21 | 2004-06-21 | Aequorin-containing compositions and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG153848A1 true SG153848A1 (en) | 2009-07-29 |
Family
ID=35785748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200904273-0A SG153848A1 (en) | 2004-06-21 | 2005-06-21 | Aequorin-containing compositions and methods of using same |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20060229243A1 (enExample) |
| EP (2) | EP1768691B1 (enExample) |
| JP (1) | JP4971150B2 (enExample) |
| KR (1) | KR101213555B1 (enExample) |
| CN (1) | CN1997383B (enExample) |
| AU (1) | AU2005265266B2 (enExample) |
| BR (1) | BRPI0512392B1 (enExample) |
| CA (1) | CA2571542C (enExample) |
| CY (1) | CY1114307T1 (enExample) |
| DK (1) | DK1768691T3 (enExample) |
| ES (1) | ES2422173T3 (enExample) |
| IL (1) | IL180195A (enExample) |
| MX (1) | MXPA06015037A (enExample) |
| NZ (1) | NZ552274A (enExample) |
| PL (1) | PL1768691T3 (enExample) |
| PT (1) | PT1768691E (enExample) |
| SG (1) | SG153848A1 (enExample) |
| SI (1) | SI1768691T1 (enExample) |
| WO (1) | WO2006010004A2 (enExample) |
| ZA (1) | ZA200610688B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
| GB0625678D0 (en) * | 2006-12-21 | 2007-01-31 | Lux Biotechnology Ltd | Composition and method for detection of demineralisation |
| MX2010009753A (es) * | 2008-03-11 | 2010-09-30 | Quincy Bioscience Llc | Composiciones que contienen apoaecuorina y metodos de uso de las mismas. |
| JP2010143860A (ja) * | 2008-12-19 | 2010-07-01 | Chisso Corp | タンパク質の安定化剤 |
| US20110130336A1 (en) * | 2009-10-16 | 2011-06-02 | Quincy Bioscience, Llc | Method of treating ischemic injury using apoaequorin |
| WO2012086756A1 (ja) * | 2010-12-24 | 2012-06-28 | 大塚製薬株式会社 | 生理活性物質を検出するバイオアッセイ法 |
| SG11201402364WA (en) * | 2011-11-15 | 2014-09-26 | Quincy Bioscience Llc | Apoaequorin for reducing neuronal injury due to ischemia |
| GB201700317D0 (en) | 2017-01-09 | 2017-02-22 | Calcivis Ltd | Detection device |
| USD1042180S1 (en) | 2020-05-28 | 2024-09-17 | Calcivis Limited | Dental detection device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001240855A (ja) * | 2000-03-01 | 2001-09-04 | Masashi Sugimoto | 生物発光方法及び発光物品 |
| US6800492B2 (en) * | 2000-06-01 | 2004-10-05 | Institute Pasteur | Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level |
| US6930169B2 (en) * | 2000-06-12 | 2005-08-16 | University Of Baltimore Biotechnology Institute | Method of controlling the binding of calmyrin to presenilin |
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
-
2004
- 2004-06-21 US US10/872,795 patent/US20060229243A1/en not_active Abandoned
-
2005
- 2005-06-21 KR KR1020077001461A patent/KR101213555B1/ko not_active Expired - Lifetime
- 2005-06-21 BR BRPI0512392-5A patent/BRPI0512392B1/pt not_active IP Right Cessation
- 2005-06-21 SI SI200531724T patent/SI1768691T1/sl unknown
- 2005-06-21 PL PL05766584T patent/PL1768691T3/pl unknown
- 2005-06-21 AU AU2005265266A patent/AU2005265266B2/en not_active Expired
- 2005-06-21 US US11/571,043 patent/US7671015B2/en not_active Expired - Lifetime
- 2005-06-21 EP EP05766584.6A patent/EP1768691B1/en not_active Expired - Lifetime
- 2005-06-21 MX MXPA06015037A patent/MXPA06015037A/es active IP Right Grant
- 2005-06-21 PT PT57665846T patent/PT1768691E/pt unknown
- 2005-06-21 CN CN200580024585XA patent/CN1997383B/zh not_active Expired - Lifetime
- 2005-06-21 JP JP2007518179A patent/JP4971150B2/ja not_active Expired - Fee Related
- 2005-06-21 SG SG200904273-0A patent/SG153848A1/en unknown
- 2005-06-21 WO PCT/US2005/021770 patent/WO2006010004A2/en not_active Ceased
- 2005-06-21 DK DK05766584.6T patent/DK1768691T3/da active
- 2005-06-21 CA CA2571542A patent/CA2571542C/en not_active Expired - Lifetime
- 2005-06-21 ES ES05766584T patent/ES2422173T3/es not_active Expired - Lifetime
- 2005-06-21 EP EP12188025.6A patent/EP2545934B1/en not_active Expired - Lifetime
- 2005-06-21 NZ NZ552274A patent/NZ552274A/en not_active IP Right Cessation
-
2006
- 2006-12-19 ZA ZA200610688A patent/ZA200610688B/en unknown
- 2006-12-19 IL IL180195A patent/IL180195A/en active IP Right Grant
-
2010
- 2010-01-27 US US12/694,427 patent/US20100152117A1/en not_active Abandoned
-
2013
- 2013-06-14 CY CY20131100486T patent/CY1114307T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1836169T3 (pl) | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek | |
| IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
| GB0515353D0 (en) | Food | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| GEP20084550B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| TW200618817A (en) | Diffractive colorants for cosmetics | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| TW200602052A (en) | Azaindoles useful as inhibitors of JAK and other protein kinases | |
| TNSN07005A1 (fr) | Analogues tetrapeptidiques | |
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MY147767A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
| MX2010003009A (es) | Piridil sulfonamidas como moduladores de canales ionicos. | |
| TW200714277A (en) | Methods and compositions for altering cell fuction | |
| GEP20115201B (en) | Cinnamoyl-piperazine derivatives and their use as par- i antagonists | |
| WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| CY1114307T1 (el) | Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| MX2010003563A (es) | Inhibidores de proteina cinasa de c-met. | |
| MX2010009753A (es) | Composiciones que contienen apoaecuorina y metodos de uso de las mismas. | |
| WO2006128143A3 (en) | Hydantoin compounds | |
| TW200700064A (en) | Novel compounds |